Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) have earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $3.83.

Several equities research analysts recently weighed in on NAUT shares. Roth Capital started coverage on Nautilus Biotechnology in a report on Tuesday, September 29th. They set a “buy” rating and a $3.50 price target for the company. Weiss Ratings raised shares of Nautilus Biotechnology from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, October 28th. Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, Zacks Research upgraded shares of Nautilus Biotechnology to a “hold” rating in a research report on Wednesday, September 30th.

Nautilus Biotechnology Stock Performance

Nautilus Biotechnology stock opened at $2.34 on Tuesday. The company has a market capitalization of $298.05 million, a P/E ratio of -5.09 and a beta of 0.73. Nautilus Biotechnology has a fifty-two week low of $0.84 and a fifty-two week high of $4.31. The stock has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $2.11.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Tuesday, October 27th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.21 million. As a group, analysts forecast that Nautilus Biotechnology will post -0.50 earnings per share for the current year.

Hedge Funds Weigh In On Nautilus Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. increased its position in Nautilus Biotechnology by 62.5% during the third quarter. TD Waterhouse Canada Inc. now owns 26,000 shares of the company’s stock worth $41,000 after buying an additional 10,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Nautilus Biotechnology in the second quarter valued at $63,000. Corient Private Wealth LP lifted its position in shares of Nautilus Biotechnology by 43.6% in the second quarter. Corient Private Wealth LP now owns 164,788 shares of the company’s stock valued at $308,000 after acquiring an additional 50,000 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of Nautilus Biotechnology during the second quarter valued at $64,000. Finally, Susquehanna International Group LLP boosted its stake in shares of Nautilus Biotechnology by 1,710.9% during the second quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock valued at $1,666,000 after acquiring an additional 841,749 shares during the last quarter. 50.71% of the stock is owned by institutional investors and hedge funds.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.